Skip to main content
Publications
Johannes CB , Beachler DC, Layton JB , Danysh HE , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE , Johannes CB , Beachler DC, Layton JB , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Forns J , Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C . Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study . Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Rebordosa C , Houben E, Laugesen K, Bothner U, Montonen J, Aguado J , Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW . No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study . Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study . Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Rebordosa C , Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J , Overbeek J, Ehrenstein V, Wallace L, Gilsenan A . Utilization of olodaterol and indacaterol in Europe . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864